SecBot SecBot
SECBOTREPLAY Home › Report › SMMT

SMMT · Partner Akeso announced statistically significant overall survival (OS)…

Summit Therapeutics Inc. · 8-K filed Sep 3, 2026 at 09:21 ET

At the news

BULLISHIMPACT 6/10

8-K filed Sep 3, 2026 at 09:21 ET

Partner Akeso announced statistically significant overall survival (OS) benefit for ivonescimab monotherapy vs pembrolizumab in the Phase III HARMONi-2 study (PD-L1-positive advanced NSCLC, China). HARMONi-2 already met its primary PFS endpoint (HR 0.51, p<0.0001) and received NMPA approval in China in April 2025. The OS win adds to ivonescimab's favorable risk/reward profile ahead of Summit's November 14, 2026 PDUFA date for HARMONi (EGFR-mutated NSCLC), while Summit's own HARMONi-7 global monotherapy study in PD-L1-high NSCLC is enrolling. This cross-filing positive readout supports Summit's ivonescimab franchise but remains a single-region China study, the pivotal confirmatory data for US/Europe approval will come from Summit's HARMONi trial.

  • Phase III HARMONi-2 showed statistically significant OS benefit for ivonescimab vs pembrolizumab monotherapy in PD-L1-positive advanced NSCLC
  • HARMONi-2 is a single-region China study by partner Akeso, data exclusively generated, managed, and analyzed by Akeso
  • Ivonescimab already approved by China's NMPA (April 2025) based on the primary PFS endpoint (HR 0.51, 95% CI 0.38-0.69, p<0.0001)
  • Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi) was accepted by FDA in January 2026; PDUFA date is November 14, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access